Key clinical point: A model that mimics the recommender system used by Netflix and Amazon can identify genomic biomarkers associated with resistance or response to lenalidomide in patients with nondeletion 5q myelodysplastic syndromes (MDS).
Major finding: The model predicted response or resistance to lenalidomide with 82% accuracy.
Study details: A retrospective study of 139 patients, 100 of whom had nondel(5q) MDS.
Disclosures: The researchers reported having no relevant conflicts of interest.
REPORTING FROM ALF 2019